Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Roche CD47 antibody start-up gives up-lays off all employees

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Jun 17, 2023 3:35pm

128 Views

Post# 35501958

RE:Roche CD47 antibody start-up gives up-lays off all employees

Prior to this and other similar news Pfizer acquired pre-clinical CD47 blockade company Trillium Therapeutics for U$2.3 Billion which re-emphasizes the point that a company's stock price does not correlate to a company's ultimate merger and acquistion (M&A) price.

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec